1. P-53 Efficacy and safety of ravulizumab in adults with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder: Outcomes from the phase 3 CHAMPION-NMOSD trial. (April 2023) Authors: Pittock, S.; Barnett, M.; Bennett, J.L.; Berthele, A.; de Sèze, J.; Levy, M.; Nakashima, I.; Oreja-Guevara, C.; Palace, J.; Paul, F.; Pozzilli, C.; Allen, K.; Mashhoon, Y.; Yountz, M.; Kim, H.J. Journal: Clinical neurophysiology Issue: Volume 148(2023) Page Start: e32 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗